Prostate cancer‐specific survival · clinically localized prostate cancer
Altered fraction schedules showed no clear difference in prostate cancer‐specific survival compared with conventional fractionation (low certainty).
1 finding from 1 review
Late gastrointestinal RT toxicity ≥ Grade II RTOG/EORTC · clinically localized prostate cancer
It is very uncertain whether altered fraction schedules changes late gastrointestinal RT toxicity ≥ Grade II RTOG/EORTC compared with conventional fractionation (very low certainty).
1 finding from 1 review
Late genitourinary RT toxicity ≥ Grade II RTOG/EORTC · clinically localized prostate cancer
Altered fraction schedules showed no clear difference in late genitourinary RT toxicity ≥ Grade II RTOG/EORTC compared with conventional fractionation (moderate certainty).
1 finding from 1 review
Overall survival · clinically localized prostate cancer
Altered fraction schedules showed no clear difference in overall survival compared with conventional fractionation (high certainty).
1 finding from 1 review
Metastasis‐free survival · clinically localized prostate cancer
Altered fraction schedules showed no clear difference in metastasis‐free survival compared with conventional fractionation (low certainty).
1 finding from 1 review
Biochemical recurrence‐free survival · clinically localized prostate cancer
Altered fraction schedules showed no clear difference in biochemical relapse‐free survival compared with conventional fractionation (moderate certainty).
1 finding from 1 review
Acute GU RT toxicity · clinically localized prostate cancer
Altered fraction schedules showed no clear difference in acute GU RT toxicity compared with conventional fractionation (moderate certainty).
1 finding from 1 review
Overall survival: higher‐dose WBRT vs control (3000 cGy/10 daily fractions)No. of participants: 846(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules probably leads to higher overall survival: lower‐dose WBRT vs control WBRT (3000 cGy/10 daily… compared with WBRT control (moderate certainty).
2 findings from 1 review
HR 1.21 [1.04, 1.4]
Studies not reported
Moderate
HR 0.97 [0.83, 1.12]
Studies not reported
Moderate
Overall survival: WBRT 4000 cGy/20 fractions BID vs control WBRT (2000 cGy/4‐5 daily fractions)No. of participants: 203(2 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in overall survival: WBRT 4000 cGy/20 fractions BID vs control WBRT… compared with WBRT control (moderate certainty).
1 finding from 1 review
HR 1.18 [0.89, 1.56]
Studies not reported
Moderate
Neurological function improvement: lower‐dose WBRT vs control dose WBRT (3000 cGy/10 fractions)No. of participants: 1612(5 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules probably leads to higher neurological function improvement: lower‐dose WBRT vs control dose… compared with WBRT control: neurological function improvement (moderate certainty).
1 finding from 1 review
OR 1.74 [1.06, 2.84]
Studies not reported
Moderate
Neurological function improvement: higher‐dose WBRT vs control dose WBRT (3000 cGy/10 fractions)No. of participants: 1480(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in neurological function improvement: higher‐dose WBRT vs control dose… compared with WBRT control: neurological function improvement (moderate certainty).
1 finding from 1 review
OR 1.14 [0.92, 1.42]
Studies not reported
Moderate
Adverse effectsNo. of participants: 1754(9 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
High
Symptom controlNo. of participants: 1814(3 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Overall brain controlNo. of participants: 203(2 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate